GlaxoSmithKline PLC (GSK)

38.89
0.41 1.04
NYSE : Health Care
Prev Close 39.30
Open 38.94
Day Low/High 38.81 / 39.07
52 Wk Low/High 37.20 / 45.58
Volume 3.01M
Avg Volume 4.17M
Exchange NYSE
Shares Outstanding 2.44B
Market Cap 95.74B
EPS 5.20
P/E Ratio 22.59
Div & Yield 1.85 (4.70%)

Latest News

'Mad Money' Lightning Round: Southwestern Energy, UnitedHealth, Celgene and More

'Mad Money' Lightning Round: Southwestern Energy, UnitedHealth, Celgene and More

Jim Cramer favors UnitedHealth over Cerner, and U.S. Concrete more than Cemex.

Jim Cramer's 'Mad Money' Recap: Don't Worry About a Little Market Detour

Jim Cramer's 'Mad Money' Recap: Don't Worry About a Little Market Detour

Get used to some down days, says Jim Cramer, but don't lose sight of the success for financial stocks.

GSK Starts Phase III Study Of Once-Daily Closed Triple Combination Therapy FF/UMEC/VI In Patients With Asthma

GSK Starts Phase III Study Of Once-Daily Closed Triple Combination Therapy FF/UMEC/VI In Patients With Asthma

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the start of a phase III study investigating the effects of once-daily closed triple combination therapy fluticasone...

How You Can Profit as the Market for COPD Drugs Grows

How You Can Profit as the Market for COPD Drugs Grows

Hundreds of millions of people worldwide suffer from chronic respiratory disease. Here's how investors can profit from the companies making strides in treating COPD.

Pfizer Takes $106 Million Fine From U.K. for Price Hike of Epilepsy Drug

Pfizer Takes $106 Million Fine From U.K. for Price Hike of Epilepsy Drug

The U.K. regulator takes exception to the sale of Epanutin to Flynn Pharma, which drove the price up by 2,600%.

How to Buy GlaxoSmithKline at a 15% Discount

How to Buy GlaxoSmithKline at a 15% Discount

Investors seeking more returns can not only get some yield, but also healthy dividends from buying options on stocks. Those who are seeking additional opportunities can purchase GlaxoSmithKline (GSK),

GSK Files Regulatory Submission In European Union For Once-Daily Closed Triple Combination Therapy FF/UMEC/VI For Patients With COPD

GSK Files Regulatory Submission In European Union For Once-Daily Closed Triple Combination Therapy FF/UMEC/VI For Patients With COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing by GSK of a regulatory submission with the European Medicines Agency for once-daily, closed triple combination therapy...

Relvar® Ellipta® 100/25 Mcg Gains Approval In Japan For Use In Patients With COPD

Relvar® Ellipta® 100/25 Mcg Gains Approval In Japan For Use In Patients With COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Relvar ® Ellipta ® (fluticasone furoate /...

10 Undervalued High-Yield Dividend Stocks Worth Buying Today

10 Undervalued High-Yield Dividend Stocks Worth Buying Today

Each dividend stock scores well for safety and has a historically high dividend yield.

2 Excellent Dividend-Paying Drug Stocks to Add to Your Portfolio

2 Excellent Dividend-Paying Drug Stocks to Add to Your Portfolio

These two pharmaceutical stocks offer great yields.

GSK Files Regulatory Submission In US For Once-Daily Closed Triple Combination Therapy FF/UMEC/VI For Patients With COPD

GSK Files Regulatory Submission In US For Once-Daily Closed Triple Combination Therapy FF/UMEC/VI For Patients With COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing by GSK of a regulatory submission with the US Food and Drug Administration for the once-daily, closed triple combination...

Here's Which Pharma Giants Might Want to Buy Pfizer's Consumer Health Unit

Here's Which Pharma Giants Might Want to Buy Pfizer's Consumer Health Unit

A sale or spinoff of this business will likely get the attention of competitors that want to increase their over-the-counter product units.

Tracing Benjamin Graham's Descendants

Tracing Benjamin Graham's Descendants

Firms' 13F filings show how they've followed in the footsteps of the father of value investing.

Here Are 3 Ways to Play the Growing Market for Vaccines Right Now

Here Are 3 Ways to Play the Growing Market for Vaccines Right Now

This market is exploding in the U.S., presenting better investment opportunities than other types of therapies.

Donald Trump Election Victory Boosts Some Stocks and Sectors

Donald Trump Election Victory Boosts Some Stocks and Sectors

As we all know, the stock market and the economy abhor uncertainty.

The Likely Market Impact of President Trump

As we all know, the stock market and the economy abhor uncertainty.

The Likely Market Impact of President Trump

As we all know, the stock market and the economy abhor uncertainty.

SBUX, AAPL, FB: Jim Cramer's Views

SBUX, AAPL, FB: Jim Cramer's Views

Cramer shares his views on the rise of the stay-at-home consumer. Starbucks, Apple and Facebook are among the stocks discussed.

Uncertain Times; Themes That Endure: Jim Cramer's Best Blogs

Uncertain Times; Themes That Endure: Jim Cramer's Best Blogs

Jim Cramer ponders the preciousness of credibility.

Cramer: Don't Just Stand There Like Bambi; Sell Some

Cramer: Don't Just Stand There Like Bambi; Sell Some

Stocks in the health care sector seem to have no underpinnings whatsoever.

Cramer: Credibility Is a Precious Market Commodity

Cramer: Credibility Is a Precious Market Commodity

And if it's lost, good luck getting it back.

European Stocks Mixed on Corporate Earnings, Brexit News

European Stocks Mixed on Corporate Earnings, Brexit News

A partial victory for Brexit opposition and mixed corporate earnings drive markets in Europe.

GlaxoSmithKline Beats Estimates in Strong Third Quarter

GlaxoSmithKline Beats Estimates in Strong Third Quarter

Britain's largest pharmaceuticals company reports growth in its HIV medicines business as it submits a shingles vaccine for FDA approval.

Novartis Beats Third-Quarter Earnings Forecasts on Growth Products, Cost Cuts

Novartis Beats Third-Quarter Earnings Forecasts on Growth Products, Cost Cuts

The group's blood cancer drug Gleevec also holds up better than expected against generic competition.

European Week Ahead: GDP Data, Consumer Poll to Measure Brexit Damage

European Week Ahead: GDP Data, Consumer Poll to Measure Brexit Damage

Forward-looking purchasing managers' indices and earnings from beleaguered lender Deutsche Bank feature among the other release highlights.

What to Watch This Week: Apple Earnings, Third Quarter GDP

What to Watch This Week: Apple Earnings, Third Quarter GDP

For the week of October 24, investors await quarterly results from a slew of major companies, including Apple, along with the first estimate of third quarter GDP.

These 5 Big-Cap Stocks Are Breaking Out After the Debate: Alphabet, Visa and More

These 5 Big-Cap Stocks Are Breaking Out After the Debate: Alphabet, Visa and More

As the dust settles on Wednesday's contentious presidential debate, U.S. markets are actually teetering on the edge of breakout territory.

Shark Tank's O'Leary Bullish on GlaxoSmithKline (GSK)

Shark Tank's O'Leary Bullish on GlaxoSmithKline (GSK)

O'Shares Investment chairman and CNBC Shark Tank investor Kevin O'Leary says GlaxoSmithKline (GSK) has a huge advantage when selling to the U.S. market.